These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9527463)

  • 1. [Education responsibility, specialty and administration information from the legal viewpoint].
    Schreiber HL
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):653-7. PubMed ID: 9527463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Patient education responsibility, specialty and administration information from the internal medicine viewpoint].
    Ludwig WD
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):657-61. PubMed ID: 9527464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Patient education responsibility, specialty and administration information from the viewpoint of the pharmaceutical industry].
    Granitza A
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):649-53. PubMed ID: 9527462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Patient education and specialty prescription information from the psychiatric viewpoint].
    Linden M
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):662-7; discussion 667-8. PubMed ID: 9527465
    [No Abstract]   [Full Text] [Related]  

  • 5. [Responsibility for patient education in drug therapy from the viewpoint of the pharmaceutical industry].
    Sander A
    Z Arztl Fortbild (Jena); 1994 Dec; 88(12):1061-3. PubMed ID: 7716983
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug information for patients. Duties of the manufacturer, pharmacist, physician, and hospital.
    Brushwood DB; Simonsmeier LM
    J Leg Med; 1986 Sep; 7(3):279-340. PubMed ID: 3490527
    [No Abstract]   [Full Text] [Related]  

  • 7. [Modification of the prescribing practice of the physician by decisions of drug committees, specialty groups and consensus conferences].
    Müller-Oerlinghausen B
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):606-10. PubMed ID: 9527451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Responsibility for patient education in drug therapy from the viewpoint of the drug industry].
    Lerch C
    Z Arztl Fortbild (Jena); 1994 Dec; 88(12):1055-60. PubMed ID: 7716982
    [No Abstract]   [Full Text] [Related]  

  • 9. [Modification of the prescribing practice of the physician by legislation with special reference to non-approved drugs].
    Bergmann KO
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):610-6. PubMed ID: 9527452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Responsibility for patient education in drug therapy--from the physician's viewpoint].
    Henschler D
    Z Arztl Fortbild (Jena); 1994 Dec; 88(12):1063-5; discussion 1065-71. PubMed ID: 7716984
    [No Abstract]   [Full Text] [Related]  

  • 11. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The patient information and education initiative.
    Rheinstein PH; McGinnis TJ; Nightingale SL
    Am Fam Physician; 1995 Dec; 52(8):2377-8, 2381-2. PubMed ID: 7484726
    [No Abstract]   [Full Text] [Related]  

  • 13. Toll-free number for reporting adverse events on labeling for human drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Oct; 73(209):63886-97. PubMed ID: 19112682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organisations question EC changes on drug information for patients.
    Watson R
    BMJ; 2009 Mar; 338():b894. PubMed ID: 19261668
    [No Abstract]   [Full Text] [Related]  

  • 15. Cisapride and patient information leaflets.
    Sukkari SR; Sasich LD
    CMAJ; 2001 May; 164(9):1276-8; author reply 1278-9. PubMed ID: 11341134
    [No Abstract]   [Full Text] [Related]  

  • 16. A defense of the learned intermediary doctrine.
    Goetz RB; Growdon KR
    Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug companies and the public. EC proposal can be defeated.
    Redding D
    BMJ; 2009 Jan; 338():b291. PubMed ID: 19174441
    [No Abstract]   [Full Text] [Related]  

  • 18. [Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany].
    Pruszydlo MG; Quinzler R; Kaltschmidt J; Haefeli WE
    Dtsch Med Wochenschr; 2008 Jul; 133(27):1423-8. PubMed ID: 18592450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient information leaflets--helpful guidance or a source of confusion?
    Bjerrum L; Foged A
    Pharmacoepidemiol Drug Saf; 2003; 12(1):55-9. PubMed ID: 12616848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Additional information].
    Kircher W
    Med Monatsschr Pharm; 1990 Jan; 13(1):1. PubMed ID: 2304412
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.